ThromboGenics to present THR-317 Pre-clinical Research Findings at the EASDec Meeting

24 May 2017

ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary

Leuven, Belgium ThromboGenics NV announced today that it will give a presentation at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting, which is being held in Budapest, Hungary from May 25-27.

The presentation “Targeting placental growth factor attenuates retinal permeability and inflammation in diabetic Akimba micewhich will be given by ThromboGenics’ scientist Dr. Tjing-Tjing Hu, will provide further pre-clinical evidence supporting the development of THR- 317. The presentation will take place at 10.00am CET, Friday 26 May.

THR-317 is a monoclonal antibody targeting placental growth factor (PlGF), which is being developed for the treatment of diabetic macular edema (DME) as a stand-alone or as a combination therapy with current anti-VEGF drugs. ThromboGenics is currently recruiting patients into a Phase II clinical trial for THR-317 in Europe. First data from this study are expected in Q1 2018.

“We are pleased to have the opportunity to present our cutting-edge research in the field of diabetic eye disease at this important meeting, said Dr. Patrik De Haes, CEO of ThromboGenics nv. There is a clear unmet medical need for improved treatment options for diabetic eye disease. ThromboGenics is focused on addressing this need and is developing multiple new therapies, including THR-317, each with the potential to improve on the current standard of care for a range of diabetic eye disease indications.